Bisacodyl Use in the Post-operative Care of Obstetrical/Gynecological (OB/GYN) Patients

Sponsor
The Cooper Health System (Other)
Overall Status
Completed
CT.gov ID
NCT01011426
Collaborator
(none)
285
1
2
38
7.5

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether Bisacodyl, 5 mg usage decreases the incidence of nausea and abdominal pain after surgery, and also decreases the number of hospitalization days.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

Postoperative ileus is defined as a disturbance in bowel motility, clinically indistinguishable from bowel obstruction, and resulting from noxious or injurious bowel insult. During abdominal surgery, this could be due to bowel manipulation or its exposure to irritants like blood or pus. This contributes to post-operative morbidity resulting in significant patient discomfort and prolonged hospital stay. The clinical picture can be variable in presentation and severity. Patients can be asymptomatic or complain of anorexia, cramping, abdominal pain, nausea and vomiting, and bloating. Severe cases can have bilious vomiting. No diagnostic test can exclude the diagnosis with certainty and presence or absence of bowel sounds on exam is unreliable. Therefore, symptoms are primarily relied on for clinical management to promote patient comfort. Postoperative ileus can increase postoperative morbidity and lengthen hospital stay.

Traditionally, patients are given nothing-by-mouth (NPO) after major abdominal or pelvic surgery to allow rest for the dysfunctional bowel because of the concern of precipitating postoperative ileus. Patients are started on a clear liquid diet and advanced accordingly when there is documentation of bowel function such as passing flatus, presence of bowel sounds, or no obvious evidence of bowel obstruction such as nausea and vomiting. This was based on the fact that colonic motility is the last to recover after abdominal surgery (usually 3-5 days) and this is less precise in patients who develop constipation. However, the small bowel returns to normal peristaltic activity within 12-24 hours and the stomach within 24-48 hours. In addition, large body of evidence indicates that early feedings and early ambulation stimulates gastrointestinal motility, reduces overall complication rates as well as improves patient comfort and satisfaction. Laxatives also increase GI motility, will permit passage of flatus and/or stool, making the surgeon more comfortable in permitting early oral feeds. This will increase patient satisfaction, increase comfort by decreasing bloating and allow faster recovery. Bisacodyl is a mild laxative and so greatly suited for study in the post-operative period. However, laxative use can itself cause cramping, abdominal pain, and bloating.

There are several studies found in the literature about the effect of early bowel stimulation in postoperative care. However, there are only three studies related to the benefit of using laxatives during postoperative care to improve bowel function and decrease incidence of postoperative ileus. The Department of OB/GYN at Ohio showed earlier return to bowel function and a decrease in hospital stay while using Fleets Phosphorate Soda (66% sodium phosphate) in patients having a radical hysterectomy. Another study was done at Hvidovre University (Demark) to identify the benefit of using Magnesium Oxide and Disodium Phosphate immediately postoperatively in patients undergoing a hysterectomy. This study showed no difference on postoperative nausea, vomiting, or pain, but decreased the length of hospitalization by one day (N = 20). In July 2007, the Department of Surgery at Mahidol University (Thailand) used Bisacodyl suppositories on the third postoperative day in patients who underwent a colectomy for colon cancer. This study showed an increase incidence of postoperative ileus. All these studies are limited by their small number of patient enrollment, and none were blinded.

Bisacodyl (Dulcolax) is an over-the-counter laxative. It is coated with a protective coating so that it will not be digested in the stomach and small intestine. Therefore, Dulcolax only takes effect in the large intestine, where the coating is dissolved. Dulcolax is metabolized by the liver with CYP450 mechanism and excreted by stool and urine. Dulcolax works in the large intestine by stimulating the nerve endings, causing muscles to contract and the contents of the bowel to empty. Dulcolax is not used as the first treatment of bowel stimulation due to the concern about imbalance of electrolytes as well as dependency. There are few studies that document any adverse effect of Dulcolax. There are several studies showing Dulcolax as one the best choices of bowel prep agents without significant discomfort or imbalance of electrolytes.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
285 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Treatment
Official Title:
Bisacodyl Use in the Post-operative Care of Obstetrical/Gynecological (OB/GYN) Patients
Study Start Date :
Apr 1, 2009
Actual Primary Completion Date :
Jun 1, 2012
Actual Study Completion Date :
Jun 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Bisacodyl

Drug: Bisacodyl
5mg po 6 hours postoperatively, repeat in 12 hours if no flatus
Other Names:
  • Dulcolax
  • Placebo Comparator: empty opague capsule

    Drug: placebo
    1 capsule po 6 hours after surgery; repeat in 12 hours if no flatus

    Outcome Measures

    Primary Outcome Measures

    1. Incidence of nausea and vomiting in the 2 groups [3-5 days]

    Secondary Outcome Measures

    1. Time to flatus [2-5 days]

    2. Length of hospitalization [2-5 days]

    3. Incidence of postoperative ileus [2-5 days]

    4. Difference in pain scale in the 2 groups (Side-effects) [2-5 days]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    12 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Obstetrical and gynecological patients undergoing abdominal surgery.
    Exclusion Criteria:
    • Subjects undergoing a bowel resection.

    • Subjects who have a nasogastric tube for bowel decompression.

    • Subjects allergic to Bisacodyl.

    • Subjects with mechanical bowel obstruction undergoing bowel resection.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cooper University Hospital Camden New Jersey United States 08103

    Sponsors and Collaborators

    • The Cooper Health System

    Investigators

    • Principal Investigator: Meena Khandelwal, MD, Cooper University Hospital, NJ

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    The Cooper Health System
    ClinicalTrials.gov Identifier:
    NCT01011426
    Other Study ID Numbers:
    • 08-148
    First Posted:
    Nov 11, 2009
    Last Update Posted:
    Jan 20, 2014
    Last Verified:
    Jan 1, 2014

    Study Results

    No Results Posted as of Jan 20, 2014